Trial · NCT06453694
Efgartigimod for the Treatment of Acute Optic Neuritis
NCT06453694, Phase 2, Recruiting, Anastasia Vishnevetsky, MD, MPH
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Efgartigimod for the Treatment of Acute Optic Neuritis. Trials, record NCT06453694. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06453694
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efgartigimod for the Treatment of Acute Optic Neuritis
- NCT number
- NCT06453694
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Anastasia Vishnevetsky, MD, MPH
- Conditions
- Optic Neuritis
- Interventions
- Efgartigimod Alfa, Placebo
- First posted
- 2024-06-12
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment Rate | 2 years | Number of enrolled participants per month |
| Primary | Study Adherence Rate | 2 years | Proportion of randomized participants who receive both doses of assigned study intervention, attend all assigned study visits, and complete at least the high contrast visual acuity, low contrast visual acuity, and Pelli-Robson assessments at all visits |
| Primary | Change in high contrast visual acuity for effect size and standard deviation estimation | 1 month | Difference in change in high-contrast visual acuity from baseline to 1 month between groups |
| Primary | Change in low contrast visual acuity for effect size and standard deviation estimation | 1 month | Difference in change in low contrast visual acuity (LCVA) (# of letters seen at 2.5% illumination) from baseline to 1 month between groups |
| Secondary | Retention rate | 2 years | Percentage of enrolled subjects who remain in the study and do not voluntarily withdraw |
| Secondary | Screen failure rate | 2 years | Percentage of participants who fail screening |
| Secondary | Pre-screen failure rate | 2 years | Percentage of participants who fail pre-screening |
| Secondary | Drug adherence rate | 2 years | Percentage of randomized participants who receive 2 full doses of their assigned study intervention |
| Secondary | Full improvement in visual acuity (high contrast) | 30 days | Proportion of participants with full improvement in high contrast visual acuity |
| Secondary | Full improvement in visual acuity (low contrast) | 30 days | Proportion of participants with full improvement in low contrast visual acuity |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06453694
GET https://conductscience.org/api/trials/v1/NCT06453694/registered?page=2